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Abstract 
 
Patients with Ewing sarcoma metastatic at skeleton and/or viscera at onset (primary disseminated) 
have a dismal prognosis and new treatments are urgently needed. The aim of the present prospective 
phase II study was to evaluate the activity of cis-diamino-platinum 120 mg/sqm every 3 weeks for 2 
courses as front-line window therapy in a cohort of children and young adults with primary 
disseminated Ewing sarcoma. Twelve consecutive patients were enrolled in the stage 1 according to 
a Simon two-stage design, and one objective response according to RECIST Criteria was observed, 
and therefore the statistical target of response rate > 8% was not achieved. For this reason, the 
accrual was stopped and CDDP as single-agent was not considered for further evaluation in primary 
disseminated  Ewing sarcoma.   
  
  
Introduction 
 
The prognosis for with Ewing sarcoma metastatic at skeleton and/or viscera at onset (primary 
disseminated) remains dismal (1-4). Standard chemotherapy for Ewing sarcoma (ES) include 
different combinations of vincristine, cyclophosphamide, ifosfamide, etoposide, doxorubicin and 
actinomycin-D (5). Recently, topotecan, irinotecan and temozolomide were included in ongoing 
front-line clinical trials due to the promising activity of these drugs in phase I-II studies in 
relapsed/refractory ES (6-10).  
Cis-diamino-platinum (CDDP) was studied in a limited number of clinical trials either in first line 
or at relapse, and results of its use as single agent are limited to one paper (11-21).   
In the present prospective study of Italian Sarcoma Group (ISG) and Associazione Italiana di 
Ematologia ed Oncologia Pediatrica (AIEOP), we evaluated the activity of two courses of CDDP as 
single agent as a front-line window therapy in a cohort of patients with primary disseminated ES at 
onset. 
 
Materials and methods 
 
The ISG/AIEOP Very-High Risk-2 (VHR-2) study (Eudract 2005-002561-36) enrolled patients 
with primary disseminated ES at onset. All scientific/ethical committees of the involved institutions 
approved the protocol, and informed consent was obtained from adult patients or from the legal 
guardians. ISG/AIEOP VHR2 consisted of CDDP 120 mg/sqm delivered in continuous infusion for 
48 hours every 3 weeks for 2 courses as front-line window therapy, followed by the intensive 
program previously described according to the ISG/SSG IV study (22). The primary aim of the 
VHR-2 study was the evaluation of the overall response rate after the 2 courses with CDDP 
according to the Response Evaluation Criteria in Solid Tumours 1.1 (RECIST) (23). Secondary end 
points included safety profile of the front-line window therapy, and outcome of the whole  VHR-2 
strategy measured as 2-year event-free survival and 2-year overall survival rates. 
Eligibility criteria included histologically proven diagnosis of ES, presence of multiple skeletal 
metastases and/or visceral metastases at onset, with/without lung metastases. Initial evaluation 
included CT or MR of the primary tumor, TC99 scan, chest and abdominal CT scan, bilateral bone 
marrow aspirate and biopsy. Measurable targets according to the RECIST criteria were mandatory 
(23). After the 2 CDDP courses (week 6), a complete re-evaluation was performed, and the 
response was evaluated with RECIST criteria. Response rate was defined as the percentage of 
evaluable patients with complete response (CR) or partial response (PR). The histological diagnosis 
and the radiological evaluation before and after the front-line therapy were centrally reviewed. Full 
blood count and serum chemistry were performed before and after each course of therapy, and 
adverse events were graded according to the NCIC criteria Version 3.0 (24). 
A Simon two-stage design was applied to assess the activity of this strategy with front-line CDDP 
therapy (25). Under the assumptions that objective response rate (ORR) ≤ 8% was considered 
unacceptable versus ≥30% ORR as acceptable and 10% types I and II error rates,12 patients were to 
be treated in the first stage. At least 2 objective responses were required to enroll additional 13 
patients in the second stage. By this design, the front-line window therapy would be considered 
ineffective if fewer than 4 responses were obtained for a cohort of 25 patients.  
Event-free survival (EFS) was defined as the period from the start of chemotherapy to the most 
recent follow-up or tumor progression/recurrence or death from treatment-related complications or 
secondary malignancy. Overall survival (OS) was calculated from the start of chemotherapy to the 
most recent follow-up or death. Survival curves were calculated according to the Kaplan and Meier 
method and compared using the log-rank test.  
 
Results 
 
In the study-period 2006-2008, 12 consecutive patients with primary disseminated ES at onset were 
enrolled in the first stage of the study. All patients received the 2 scheduled courses with CDDP and 
were eligible for response evaluation. Demographics are depicted in Table 1. Responses are 
described in Table 2. The response rate was 8%, since 1/12 obtained a PR. The characteristics of 
this patient have been previously described (26). Stable disease (SD) was observed in 9 (75%) and 2 
patients had progressive disease (17%) after the second course CDDP.  
The major toxicity of the two courses CDDP was hematological. Grade 3-4 neutropenia and grade 
3-4 thrombocytopenia occurred after 37% and after 49% of courses, respectively. Platelet 
transfusions were given after 4 courses  (2 patients-1 unit; 1 patient-2 units), while packed red cell 
transfusions were given after 5 courses in 4 patients (median: 2 units, range 1-4). Additional acute 
toxicities recorded were grade 3 nausea and grade 3 vomiting during 2 courses in 2 patients, and 
transient grade 1 hypokalemia during 3 courses (2 patients). 
Two-year EFS probability was 0.15 ± 0.14 and 2-year OS probability was 0.22 ± 0.12. The median 
time to disease progression/relapse with the ISG/AIEOP VHR-2 treatment plan was 11 months 
(range 1–35). Only one patient (pt #7) is long-term survivor, relapse-free 8 years after the end of the 
treatment  (26). 
 
Discussion  
CDDP has synergistic effects with other agents in pre-clinical models in ES (27). After the first 
promising results obtained three decades ago as a single agent, CDDP was included in different 
phase II trials in relapsed ES (11-18). The responses rates ranged from 18% 
(cisplatinum+etoposide) to 29-51% (CDDP + ifosfamide + etoposide). (11-18). In this setting, the 
activity of every single agent was jeopardized by the concomitant use of different drugs and, 
therefore, it was not possible to determine the contribution, if any, of CDDP to the response rate. 
However, despite an interesting response-rate, the survival probabilities with the combinations that 
included CDDP were not superior to other combinations not including CDDP, and were even 
comparable to the results obtained with oral etoposide alone (6-10,28,29).  
Other platinum compounds were tested in resistant/ relapsed ES. Carboplatin is an analogue of 
cisplatin with less non-hematologic toxicity than the parent compound (30). Although single agent 
data in carboplatin was limited, combinations of carboplatin + etoposide and ifosfamide or 
cyclophosphamide have shown promise in relapsed paediatric sarcomas including also ES. These 
combinations resulted in a substantial response rate in previously treated patients, but with 
significant toxicity and short-time responses (16, 31-34). Oxaliplatin, a third generation platinum 
agent containing a DACH (1, 2 diaminocyclohexane) carrier ligand, was developed to provide a less 
toxic and more effective platinum compound (35). Despite a favourable toxicity prophile, 
oxaliplatin administered as a single agent had limited activity in childhood relapsed or refractory 
solid tumors, including ES, where 1 stable disease and 9 progressions were observed in 10 
evaluable patients (36).  
The peculiarity of the present prospective study is the use of CDDP as single agent in a front-line 
setting deemed as the most appropriate to ascertain the real activity of this drug in this sarcoma. 
One objective response (8%) in the stage 1 cohort with 12 consecutive patients enrolled was 
observed, and therefore the statistical target of RR > 8% was not achieved. For this reason, the 
accrual was stopped and CDDP as single-agent was not considered appealing for further evaluation. 
The 2-year EFS and 2-year OS probabilities obtained with ISG/AIEOP VHR-2 confirmed the lack 
of impact of the use of 2 courses CDDP on the outcome. These results are in fact comparable with 
those obtained with the previous AIEOP/ISG VHR1 study and with those reported in literature (1-
6,37,38). Despite this negative result, one patient treated with CDDP obtained a partial response 
that traced the path for the achievement of a complete remission with the following treatment 
according to the Study Protocol (26). 
In conclusion, the results obtained with the present study in a front-line setting confirm a limited 
activity of CDDP in the treatment of Ewing’s sarcoma. 
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Table 1. Patient characteristics at diagnosis 
 
Pt # Age Site of the primary 
tumor 
Bone  
metastases 
Lung  
metastases 
Bone 
marrow 
 infiltration 
Other  
metastatic sites 
1 7 Vertebra Yes Yes No No 
2 14 pelvis Yes Yes No No 
3 18 pelvis Yes No No No 
4 21 vertebra No Yes No Yes (liver) 
5 36 vertebra Yes No No No 
6 7 Tibia Yes Yes Yes No 
7 10 humerus Yes No No Yes (distant lymph 
nodes) 
8 10 pelvis Yes No No Yes (distant lymph 
nodes) 
9 13 vertebra Yes No No No 
10 12 scapula Yes No Yes No 
11 
14 
paravertebral , C7-
D1 
Yes No No No 
12 19 femur Yes Yes No No 
 
  
Table 2. Response to the front-line therapy with CDDP according to RECIST Criteria 
 
Pt # Site of the  
primary 
tumor 
Bone  
metastases 
Lung  
metastases 
Other  
metastatic 
sites 
Non target 
lesions 
New 
lesions 
Overall 
response 
1 SD NE PD  PD Yes PD 
2 SD SD SD  SD No SD 
3 SD SD    No SD 
4 SD  PR PD  Yes PD 
5 SD SD    No SD 
6 SD SD   SD NE SD 
7 PR PR  PR  No PR 
8 PR PD  PD SD No PD 
9 SD SD    No SD 
10 SD SD   CR No SD 
11 SD SD    No SD 
12 PD PD PD   Yes PD 
CR, complete remission; PR, partial remission; SD , stable disease; PD, progressive disease; NE, 
not evaluated 
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